Study of TRC102 in Combination With Pemetrexed in Cancer Patients
This study is being performed to evaluate the safety and tolerability of TRC102 in combination with Alimta. In addition to safety, this study will also evaluate pharmacokinetics and tumor response.
Neoplasm
DRUG: TRC102 + pemetrexed
To determine the recommended Phase 2 dose and overall safety and tolerability of TRC102 when given alone and when combined with pemetrexed for the treatment of patients with advanced solid or metastatic cancer for whom curative therapy is unavailable., Study completion
Characterize pharmacokinetics, assess anti-tumor activity, and assess pharmacodynamics, Study completion
This study is being performed to evaluate the safety and tolerability of TRC102 in combination with Alimta. In addition to safety, this study will also evaluate pharmacokinetics and tumor response.